TrakCel’s Post

New research has uncovered promising potential ways to personalize treatment for mesothelioma. The use of sequencing technology has played a crucial role in the study of this disease, allowing us to gain a better understanding of its genetic composition. One significant finding is that genetic issues are present in over 20% of cases, particularly affecting tumor suppressor genes. Additionally, a small percentage of individuals with mesothelioma have mutations in genes that promote cancer growth. To delve deeper into sequencing technology and its impact on mesothelioma research, visit https://buff.ly/48mLOY2 #mesothelioma #sequencingtechnology #vogelzanglaw

We've been studying the rarer histotypes of ovarian cancer as a part of a large international effort and collaboration. Patients with these types of tumours are often overlooked in the scientific community, but it's crucial to understand their disease as they present very few risk prediction options for the families as well as few treatment options. Check out our preprint that offers insights into the genetic landscape of these histotypes, and stay tuned for more papers to come!!

#transcript Mark McDonough CEO of ChromaCode is leveraging high-definition PCR testing to overcome the limitations of conventional PCR to identify biomarkers of infectious diseases & cancer. While gene sequencing can provide valuable information, it requires more tissue, is expensive, & requires at least a week for analysis. Using HDPCR, ChromaCode has developed a lung cancer assay that looks at nine genes and 15 biomarkers, requiring less tissue, performed at a lower cost, & provides results quickly. This approach, built on a cloud-supported multiplexing platform, provides flexibility to explore other areas in oncology and transplants, looking at multiple targets per sample. chromacode.com https://lnkd.in/gpFTHePw

Discover how our AI technology is revolutionizing cancer treatment at Aichi Cancer Center. By analyzing over 1.2 million medical records, we're identifying effective drug candidates for specific gene mutations. Learn how this partnership enhances patient care: https://okt.to/ovrpL6 #HealthyLiving #AI #CancerTreatment #Healthcare #Fujitsu #FujitsuPortugal

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Dana-Farber, Brigham breakup could lead to a ripple effect for CGT clinical trials for cancer: Dana-Farber Cancer Institute announced on Sept. 14 that it is securing a new joint venture with Beth Israel Deaconess Medical Center, marking a breakup of its decadeslong adult cancer care partnership with Brigham and Women’s Hospital. The news shocked Brigham, which had been negotiating a partnership extension with Dana-Farber for the past 15 months, according to the Boston Globe. There are around 20 ongoing cell therapy clinical trials under the Dana-Farber Brigham Cancer Center, which comprises 12 treatment centers with experts from Dana-Farber and Brigham working together. Brigham also has its own gene and cell therapy institute and a lab dedicated to next-generation, genetically-modified CAR-T cell therapies for cancer. With the Dana-Farber contract set to end in 2028, concerns have been raised about the impact on current cell and gene therapy (CGT) studies and ones that are scheduled to start, due to the complex nature of the treatments involved. Jason Foster Manufacturing CGTs is a skill- and labor-intensive process. Ori Biotech CEO Jason Foster told Endpoints News that hospitals and research centers often work together to make them on-site for clinical trials, with highly skilled experts from the specialty centers playing a key role. UK-based Ori develops technologies that automates CGT manufacturing. At Dana-Farber Brigham Cancer Center’s cellular therapies program, cells are processed at an outside commercial facility or at the Connell and O’Reilly Families Cell Manipulation Core Facility. When such partnerships come to an end, “that kind of [specialist] knowledge loss is something that will impact both the trajectory of [CGT] trials, but also the time it takes to get these products to patients,” Foster added. These potential negative impacts on trials would only compound preexisting barriers to access to CGTs, including high costs and lengthy manufacturing processes. Estimates suggest that 25% of patients die while waiting for CAR-T treatments, according to ASCO Post. Lee Buckler Lee Buckler, senior vice president of advanced therapies at Blood Centers of America, told Endpoints in an email that collaboration between research institutes and healthcare providers was of significant — if not critical — value to the testing of CGTs. A Brigham spokesperson said that the hospital is one of the largest recipients of NIH funding and does not expect any changes to trials already under agreement, adding it would continue to be a leader in the CGT space. “We are also planning for a new, state of the art Brigham facility which will include the medical oncology specialty,” the spokesperson said. Dana-Farber did not respond to Endpoints before… #lucidquest #genetherapy #celltherapy

This is a treasure trove of data and so valuable as we continue to evolve to build precision medicine pathways. Great to see that longitudinal data is available but still many challenges to meet in delivering seamless testing analysis and interventions. #precisionmedicine #biomarkers #genomics

Proud to share our latest work, just published in Nature Communications https://lnkd.in/gAHdQC4H. This study is spearheaded by my outstanding PhD student, Daniel Aron Ang, and talented Research Fellow, Jean-Michel Carter, together with the great help of Kamalakshi Deka. We are also grateful for the invaluable contributions from our collaborators’ labs, Wee Joo Chng, Qingfeng Chen and Nathan Harmston, and funding support from National Research Foundation Singapore. Here, we characterise the epigenome under constitutive activation of the non-canonical NF-kB pathway in multiple myeloma. We demonstrate that activating mutations in this pathway can unlock access to a diverse range of p52-responsive enhancers to potentiate oncogenic expression and MM progression. #multiplemyeloma #cancer #epigenomics #NTUsg

Gene&Cell Therapy >> Dana-Farber, Brigham breakup could lead to a ripple effect for CGT clinical trials for cancer: Dana-Farber Cancer Institute announced on Sept. 14 that it is securing a new joint venture with Beth Israel Deaconess Medical Center, marking a breakup of its decadeslong adult cancer care partnership with Brigham and Women’s Hospital. The news shocked Brigham, which had been negotiating a partnership extension with Dana-Farber for the past 15 months, according to the Boston Globe. There are around 20 ongoing cell therapy clinical trials under the Dana-Farber Brigham Cancer Center, which comprises 12 treatment centers with experts from Dana-Farber and Brigham working together. Brigham also has its own gene and cell therapy institute and a lab dedicated to next-generation, genetically-modified CAR-T cell therapies for cancer. With the Dana-Farber contract set to end in 2028, concerns have been raised about the impact on current cell and gene therapy (CGT) studies and ones that are scheduled to start, due to the complex nature of the treatments involved. Jason Foster Manufacturing CGTs is a skill- and labor-intensive process. Ori Biotech CEO Jason Foster told Endpoints News that hospitals and research centers often work together to make them on-site for clinical trials, with highly skilled experts from the specialty centers playing a key role. UK-based Ori develops technologies that automates CGT manufacturing. At Dana-Farber Brigham Cancer Center’s cellular therapies program, cells are processed at an outside commercial facility or at the Connell and O’Reilly Families Cell Manipulation Core Facility. When such partnerships come to an end, “that kind of [specialist] knowledge loss is something that will impact both the trajectory of [CGT] trials, but also the time it takes to get these products to patients,” Foster added. These potential negative impacts on trials would only compound preexisting barriers to access to CGTs, including high costs and lengthy manufacturing processes. Estimates suggest that 25% of patients die while waiting for CAR-T treatments, according to ASCO Post. Lee Buckler Lee Buckler, senior vice president of advanced therapies at Blood Centers of America, told Endpoints in an email that collaboration between research institutes and healthcare providers was of significant — if not critical — value to the testing of CGTs. A Brigham spokesperson said that the hospital is one of the largest recipients of NIH funding and does not expect any changes to trials already under agreement, adding it would continue to be a leader in the CGT space. “We are also planning for a new, state of the art Brigham facility which will include the medical oncology specialty,” the spokesperson said. Dana-Farber did not respond to Endpoints before deadline. Problems with CGT trials could be… #lucidquest #genetherapy #celltherapy